Blueprint Medicines Corporation Stock News

SINGAPORE, May 24, 2020 (PR Newswire Europe via COMTEX) -- Singapore medtech company HistoIndex [https://www.histoindex.com/]'s AI-based stain-free digital...

Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector. Surface Oncology Inc (...

The FDA issues a CRL to Blueprint Medicines' (BPMC) NDA for Ayvakit to treat adults with unresectable/metastatic fourth-line GST.

One hit, one miss for GIST patients as FDA approves Deciphera’s Qinlock and rejects Blueprint Medicine’s Ayvakit as fourth-line therapy

Shares of the company fell 3.5% to $62.02 in premarket trading. The regulator in its so-called complete response letter said that Blueprint's application could not be approved in the current form. T

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug

Q1 2020 Blueprint Medicines Corp Earnings Call

Q1 2020 Blueprint Medicines Corp Earnings Call

Blueprint Medicines (BPMC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to present updated cli

Blueprint Medicines (BPMC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Blueprint Medicines (BPMC) betters loss estimates while revenues beat the mark in the first quarter. Higher collaboration revenues and a surge in product sales aid results.

Ladies and gentlemen, thank you for standing by, and welcome to the Blueprint Medicines conference call. This is Kristin Hodous of Blueprint Medicines, and welcome to Blueprint Medicines' first-quart

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 1.86% and 27.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provide